How should we assess the clinical and cost effectiveness of histology independent cancer drugs?

BMJ. 2020 Jan 2:368:l6435. doi: 10.1136/bmj.l6435.

Authors

Sophie Cooper¹, Jacoline C Bouvy², Lawrence Baker³, Francois Maignen¹, Pall Jonsson¹, Peter Clark⁴, Stephen Palmer⁵, Meindert Boysen¹, Nick Crabb¹

Affiliations

¹ National Institute for Health and Care Excellence (NICE), 10 Spring Gardens, London SW1A 2BU, UK.
² National Institute for Health and Care Excellence (NICE), 10 Spring Gardens, London SW1A 2BU, UK jacoline.bouvy@nice.org.uk.
³ Massachusetts Institute of Technology, USA.
⁴ NHS England, UK.
⁵ Centre for Health Economics, University of York, UK.

PMID: 31896539
DOI: 10.1136/bmj.l6435

No abstract available

MeSH terms

Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Cost-Benefit Analysis
Drug Approval / organization & administration
England
Europe
Evidence-Based Medicine
Humans
Neoplasms / drug therapy*
Neoplasms / economics
Technology Assessment, Biomedical
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents